Abstract
Immune checkpoint inhibitors (ICIs) have transformed oncology, yet they introduce a spectrum of immune-related adverse events (irAEs). This report details a rare and challenging case of tracheobronchial chondritis in a 66-year-old male following Nivolumab therapy for hypopharyngeal carcinoma. After 23 cycles of treatment, the patient presented with fever, cough, and significant airway narrowing. While initial high-dose steroids provided temporary relief, the condition proved refractory during tapering. Matrix metalloproteinase-3 (MMP-3) was identified as a superior biomarker for monitoring disease activity compared to C-reactive protein (CRP). Remission was ultimately achieved through a novel combination of the IL-6 receptor antagonist tocilizumab and colchicine.
Introduction
Nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, is widely used for various malignancies. However, its use can trigger autoimmune-like inflammation in nearly any organ system. Tracheobronchial chondritis—inflammation of the airway cartilage—is an exceptionally rare irAE that mimics relapsing polychondritis. Due to its rarity, diagnosis is often delayed, and standardized treatment protocols are non-existent. This case highlights the diagnostic pitfalls and the necessity of multimodal immunosuppression in refractory cases.
Case Presentation and Diagnosis
A 66-year-old male with a history of hypopharyngeal carcinoma treated with chemoradiotherapy and surgery presented with fever, cough, and malaise after 54 weeks of Nivolumab therapy. Initial clinical suspicion leaned toward bacterial pneumonia; however, imaging revealed a more complex pathology.
Contrast-enhanced CT scans were pivotal, showing a dramatic thickening of the tracheal wall—measuring 6.9 mm, compared to a baseline of 1.3 mm. This thickening resulted in a 49.6% narrowing of the airway lumen.
Bronchoscopy confirmed these findings, showing severe mucosal inflammation and swelling that compromised the airway. These diagnostic features, combined with the absence of typical lung infiltrates, pointed toward a diagnosis of Nivolumab-induced tracheobronchial chondritis.
The Biomarker Breakthrough: MMP-3 vs. CRP
A significant challenge in managing this case was the unreliability of standard inflammatory markers. C-reactive protein (CRP) initially normalized following steroid pulse therapy, suggesting resolution. However, the patient experienced clinical flare-ups even as CRP levels remained low.
Clinicians discovered that Matrix Metalloproteinase-3 (MMP-3), an enzyme associated with cartilage destruction, was a far more accurate indicator of localized disease activity. During flare-ups, MMP-3 surged to 1,065.5 ng/mL (normal range: 36.9–121 ng/mL). Tracking MMP-3 allowed the team to adjust therapy more precisely than would have been possible using systemic markers alone.
Therapeutic Management
The patient’s condition was initially treated with high-dose methylprednisolone pulse therapy, which led to rapid symptomatic improvement. However, the chondritis relapsed as the steroid dose was tapered.
To manage this refractory inflammation, the team introduced a multimodal approach:
- Methotrexate: Initially attempted but discontinued due to a secondary infection.
- Tocilizumab (TCZ): An IL-6 receptor antagonist was administered to target the underlying cytokine storm.
- Colchicine: Added to inhibit neutrophil activity within the cartilage.
Following nine doses of tocilizumab and the addition of colchicine, MMP-3 levels stabilized, and the steroid dose was successfully tapered to 10 mg/day without further relapse for over eight months.
Conclusion
Tracheobronchial chondritis is a life-threatening irAE that requires high clinical suspicion, as it easily mimics common respiratory infections. This case demonstrates that when standard steroid therapy fails, clinicians should consider localized biomarkers like MMP-3 to monitor disease activity. Furthermore, the successful use of tocilizumab and colchicine provides a potential salvage pathway for patients with refractory airway inflammation induced by immune checkpoint inhibitors.
Summary updated